BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：7
|
作者：
Taylor, Peter [1 ]
Genovese, Mark [2 ,3 ]
Keystone, Ed [4 ]
Schlichting, Douglas [5 ]
Beattie, Scott [6 ]
Macias, William [5 ]
机构：
[1] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England
[2] Immunol & Rheumatol Clin, Stanford, CA 94305 USA
[3] Stanford Univ, Palo Alto, CA 94304 USA
[4] Mt Sinai Hosp, Rebecca MacDonald Ctr Arthrit & Autoimmune Dis, Toronto, ON M5T 3L9, Canada
[5] Eli Lilly & Co Corp Ct, Indianapolis, IN USA
[6] Eli Lilly & Co, Global Stat Sci Autoimmune Platform, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2013-205124.71
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A1.72
引用
收藏
页码：A31 / A31
页数：1
相关论文
共 50 条
  • [31] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Chan, Gary
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S328 - S328
  • [32] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Soonasra, Arif
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S413 - S414
  • [33] LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4
    Feist, E.
    Nasonov, E.
    Luggen, M.
    Fatenejad, S.
    Grishin, S.
    Samsonov, M.
    Fleischmann, R. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 593 - 593
  • [34] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
  • [35] The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study
    Calvo-Garcia, Alberto
    Herraiz, Esther Ramirez
    Cubas, Irene Maria Llorente
    De Dios, Blanca Varas
    Gonzalez, Juana Benedi
    Baladron, Alberto Morell
    Garcia-Vicuna, Rosario
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [36] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
    Papp, Kim A.
    Krueger, James G.
    Feldman, Steven R.
    Langley, Richard G.
    Thaci, Diamant
    Torii, Hideshi
    Tyring, Stephen
    Wolk, Robert
    Gardner, Annie
    Mebus, Charles
    Tan, Huaming
    Luo, Yingchun
    Gupta, Pankaj
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
  • [37] TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Wei, Shu Chen
    Damiao, Aderson O.
    Judd, Donna
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1191
  • [38] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    GUT, 2018, 67 : A62 - A63
  • [39] Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Wollenhaupt, Juergen
    Lee, Eun-Bong
    Curtis, Jeffrey R.
    Silverfield, Joel
    Terry, Ketti
    Soma, Koshika
    Mojcik, Chris
    DeMasi, Ryan
    Strengholt, Sander
    Kwok, Kenneth
    Lazariciu, Irina
    Wang, Lisy
    Cohen, Stanley
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [40] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Ruediger B. Mueller
    Hendrik Schulze-Koops
    Daniel E. Furst
    Stanley B.  Cohen
    Kenneth Kwok
    Lisy Wang
    Tim Killeen
    Johannes von Kempis
    Clinical Rheumatology, 2022, 41 : 1045 - 1055
12345